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Abstract
Objectives—We examined the effect of switching to second-line antiretroviral therapy (ART) on
mortality in patients who experienced immunological failure in ART programmes without access
to routine viral load monitoring in sub-Saharan Africa.
Design and setting—Collaborative analysis of two ART programmes in Lusaka, Zambia and
Lilongwe, Malawi.
Methods—We included all adult patients experiencing immunological failure based on WHO
criteria. We used Cox proportional hazards models weighted by the inverse probability of
switching to compare mortality between patients who switched and patients who did not; and
between patients who switched immediately and patients who switched later. Results are
expressed as hazard ratios (HR) with 95% credible intervals (95% CI).
Results—Among 2,411 patients with immunological failure 324 patients (13.4%) switched to
second-line ART during 3932person-years of follow-up. The median CD4 cell count at start of
ART and failure was lower in patients who switched compared to patients who did not: 80 versus
155 cells/μL (p<0.001) and 77 versus 146 cells/μL (p<0.001), respectively.Adjusting for baseline
and time-dependent confounders, mortality was lower among patients who switched compared to
patients remaining on failing first-line ART: HR0.25 (95%CI 0.09-0.72). Mortality was also lower
among patients who remained on failing first-line ART for shorter periods: HR 0.70 (95% CI
0.44-1.09) per 6 months shorter exposure.
Conclusion—In ART programmes switching patients to second-line regimens based on WHO
immunological failure criteria appears to reduce mortality, with the greatest benefit in patients
switching immediately after immunological failure is diagnosed.
Correspondence to Professor Matthias Egger, Institute of Social and Preventive Medicine (ISPM), University of Bern,
Finkenhubelweg 11, CH-3012 Bern, Switzerland. egger@ispm.unibe.ch.
NIH Public Access
Author Manuscript
AIDS. Author manuscript; available in PMC 2013 September 02.
Published in final edited form as:
AIDS. 2012 January 2; 26(1): 57–65. doi:10.1097/QAD.0b013e32834e1b5f.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
72
92
 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
Introduction
The World Health Organization (WHO) estimates that over 6.6 million HIV-1 infected
people were receiving antiretroviral therapy (ART) in low- and middle-income countries by
the end of 2010[1]. As access to HIV treatment continues to expand, more people are
experiencing treatment failure and use of second-line therapy is increasing [2]. In contrast to
industrialized countries, where HIV-1 viral load is regularly measured, viral load monitoring
is typically not available in the public-sector in resource-limited settings. At present, viral
load monitoring is expensive and the necessary laboratory infrastructure is difficult to
implement and maintain, particularly in rural areas.
In the absence of viral load monitoring, diagnosis of treatment failure relies on
immunological (i.e. CD4 cell counts) and clinical criteria [3]. The ability of CD4 cell counts
to predict virological failure is, however, limited: sensitivity and positive predictive value of
the immunological WHO criteria for virological treatment failure have been shown to be
poor [4]. Use of these criteria may therefore lead to unnecessary switching to second-line
ART among patients with suppressed viral replication, and care givers appear to be reluctant
to switch patients to second-line ART based on CD4 cell criteria: we previously found that
in programmes relying on CD4 cell count monitoring patients switch later and at lower CD4
cell counts compared to programmes with access to viral load monitoring [5].
We know of no trials where patients meeting immunological failure criteria were
randomized to remaining on first-line therapy or switching to second-line therapy, or to
immediateversus delayed switching. In cohort studies confounding may distort associations
between clinical outcomes and switching. Confounding by indication will bias results if
switching is more likely in patients with lower CD4 cell counts at the time of
immunologicalfailure, patients who are also more likely to die.Similarly, CD4 cell counts
measured after failure may both affect the probability of subsequent switching and
mortality; unlike standard confounders, however, time-updated CD4 cell counts may
themselves be affected by prior switching decisions. Such time-dependent confounding can
be seen as a special case of confounding by indication [6], which cannot be controlled for by
standard multivariable adjustment.
We used marginal structural models and inverse probability weighting[7-9]to overcome this
problem and estimate the effect of switching to second-line ART on all cause mortality in
patients who experienced immunological failure in sub-Saharan Africa.
Methods
The International epidemiological Databases to Evaluate AIDS
The International epidemiological Databases to Evaluate AIDS (IeDEA) is a global research
consortium with seven regional networks (including four networks in sub-Saharan Africa) to
collect clinical and epidemiological data on HIV-infected people, and particularly patients
on ART. The African networks of IeDEA have been described in detail elsewhere[10]. The
Southern African region of IeDEA-SA includes ART programmes located in six countries
(Botswana, Malawi, Republic of South Africa, Zambia, Mozambique, Zimbabwe). For the
present study we included two well established ART programmes that rely on CD4 cell
counts to detect treatment failure: the Ministry of Health (MoH)-Centre for Infectious
Disease Research in Zambia (CIDRZ) programme in Lusaka, Zambia and the Lighthouse
clinic at Kamuzu Central Hospital in Lilongwe, Malawi. The MoH-CIDRZ programme
began to provide ART in 2004 across four sites in Lusaka. Since then, the programme has
expanded to 68 facilities across four provinces, most of them government health centres and
hospitals.
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In both programmes, clinical care is provided according to the national guidelines. During
the study period individuals were eligible for treatment if (i) they were diagnosed with a
stage IV condition according to World Health Organization (WHO) criteria; (ii) their CD4
cell count was below 200 cells/μL; or (iii) they had a stage III condition and their CD4 cell
countwas between 200 and 350 cells/μL. Clinical and immunological monitoring occurred
every 3 to 6 months. Viral load testing is available in Lusaka and Lilongwe and some
patients in whom treatment failure is suspected are tested. In Lusaka viral load testing is
generally performed if the clinical situation of the patient is perceived to be discordant with
the CD4 cell count[11]. In Lilongwe some patients with immunological or clinical failure
are tested. In both sites viral load testing is limited for reasons of cost and operational
constraints.
Inclusion criteria and definitions
We included patients aged >16 years experiencing immunological failure after January 1,
2004 based on any of the three WHO criteria: (i) CD4 cell counts staying persistently <100
cells/μL, (ii) a fall of CD4 cell counts below the baseline count, or (iii) a fall of >50% from
the peak value. Clinical stage was categorised into stage III or IV (advanced) and I or II (less
advanced). Loss to follow-up was defined as not returning to the clinic for 12 months or
longer.
Statistical methods
We split data into 3-month intervals (quarters). If no CD4 value was measured in a
particular quarter, the last measured value was carried forward. Patients were followed up
from the time of immunological failure to the date of database closure, death, or loss to
follow up (i.e., 12 months after the last observed visit), whichever came first. We then
estimated the causal effect of switching on mortality using two marginal structural models
[9, 12]. In the first model switching history was summarized ascurrent use of second-line
therapy, while the second model contained in addition the time spent on first-line therapy
since immunological failure. In both modelsthe following baseline covariates were used:
CD4 cell count (<50, 50-99, 100-199, ≥ 200 cells/μL), age (<30, 30-39, >40 years), sex, and
clinical stage (advanced versus less advanced).The parameters of these marginal structural
models were estimated using inverse probability of treatment weights (IPTW) [9].
In additional analyses we studied the causal effect of switching on mortality in patients who
did versus those who did not have a viral load measurement between 6 months after starting
ART and immunological failure, by including a term for the interaction between the
availability of viral load measurements and switching in the outcome model, and including
the availability of viral load measurement as predictor in the weight models. We
investigated this issue further by estimating the causal effect of switching on mortality in
patients from sites in the MoH-CIDRZ programme known to have no access to viral load
measurements, and by including availability of a viral load measurement prior to switching
as an additional time dependent confounder. Finally different models for the weights were
investigated. The model is described in more detail in the Appendix.
All analyses were done in R-2.12.1 (R Project, University of Vienna, Austria) and Stata
version 11 (Stata Corporation, College Station, TX, USA), and run independently at ETH
Zurich and at ISPM Bern.Models were fit using Bayesian methodology with weakly
informative prior distributions [13]. Results are reported as adjusted hazard ratios (HRs)
with 95% credibility intervals (CI) and conditional survival curves with 95% CIs.
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Results
Of 80,937 patients starting ART, 2,411 patients met eligibility criteria and experienced
immunological failure in the period 2004 to 2009, including 2317 patients (96.1%) from
Zambia and 94 patients (3.9%) from Malawi. A total of 324 patients (13.4%) switched to a
second-line ART regimen during 3932 person-years of follow-up, for anincidence of
switching of 82.3 (95% CI 73.7-91.6) per 1000 person-years. Seventy-six patients died, for
an incidence of death of 19.2 (15.2-23.9) per 1000 person years and 177 patients were lost to
follow-up for an incidence of 44.9 (38.6-51.89) per 1000 person-years. Incidence of loss to
follow-up was lower among patients who did versus those who did not switch to a second-
line regimen, 14.2 (6.8-25.9) versus 50.5 (43.2-58.5)per 1000 person-years (p<0.001),
respectively.
Patient characteristics
The age distribution at the start of ART was similar in patients who switched and patients
who did not, with a median age of 26 years and 27 years, respectively (Table 1). In both
groups there were slightly more women than men and close to three quarters of patients
were in advanced clinical stages (WHO stage III or IV). The median CD4 cell count at the
start of ART and at immunological failure was lower in patients who switched than in
patients who did not: 80 versus 155 cells/μL (p<0.001) and 77 versus 146 cells/μL
(p<0.001), respectively. The most frequent first-line regimen consisted of Lamivudine
(3TC), zidovudine (AZT) and nevirapine (NVP), followed by 3TC, stavudine (d4T) and
NVP (Table 2). In both groups over 90% of patients started with one of these two regimens.
Among patients who switched, the most frequent second-line regimen consisted of
emitracibine (ETC), lopinavir (LPV) and tenofovir (TNV), followed by abacavir (ABC),
didanosine (ddI) and LPV.
Predictors of switching to second-line ART
In the multivariate Cox model, patients with higher current CD4 counts were less likely to
switch to second line therapy: the HR per 100 cells/μL increase was 0.49 (p<0.001). Other
covariates were not significantly associated with switching, although there was a trend
towards a lower probability of switching among patients with baseline CD4 counts above 50
cells/μL (Table 3).
Effect of switching on mortality
After adjusting for baseline and time-dependent confounders, the hazard of death among
patients who had switched to second-line therapy immediately after failure was significantly
lower than that ofpatientswho remained on an immunologically failingfirst-line regimen(HR
0.25, 95% CI 0.09 – 0.72, p=0.01, upper panel of Figure 1). There was also a trend towards
lower mortality among patients withshorter exposure to first-line therapy after
immunological failure (HR 0.70 per 6 months shorter exposure, 95% CI 0.44 – 1.09, p=0.11,
lower panel of Figure 1). These estimated causal hazard ratios were smaller than the crude
(unadjusted) hazard ratios and the hazard ratios adjusted for baseline variables only. Figure
2 shows survival curves based on estimates from the weighted Cox models for women
younger than 30 years in WHO clinical stage III/IV with baseline CD4 cell count between
100 and 199 cells/μL. Immediate switching resulted in an estimated97.6% (95% CI
92.3%-99.2%) survival at 5 years, compared to an estimated survival of 91.3% (95% CI
84.7%-94.9%) among women who remained on a first-line regimen. The estimated survival
at 5 years among women switching 6 months, 12 months and 18 months after
immunological failure was 96.6% (95% CI 91.7%-98.4%), 95.6% (95% CI 90.9%-97.7%)
and 94.7% (95% CI 89.9%-97.2%), respectively.
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Sensitivity analyses
Overall 655 patients (27.2%) had at least one viral load measured between 6 months after
starting ART and immunological failure. Viral load measurements were more common
among patients who switched (159 patients [49.1%]) than among those who did not switch
(496 patients [23.8%], p<0.001). Detectable viral loads (>400 copies/ml)were measured in
137 patients (86.2%) and 150 patients (30.2%), respectively (p<0.001). The estimated HRs
for switching in patients who did and did not have viral load measurementswere0.13 (95%
CI 0.02-0.93) and 0.40 (95% CI 0.13-1.31), respectively (p=0.30 for difference), and the
estimated HR including availability of a viral load test as a time dependent confounder was
0.44 (95% CI 0.20- 0.99). When only considering patients from sites with no viral load
measurements in the MoH-CIDRZ programme the HR was 0.46 (95% CI 0.09-2.44).
Finally, the causal effect of switching from the main analysis was insensitive to the different
weight models, with HRs ranging between 0.20 and 0.30.
Discussion
The accuracy of the WHO CD4 cell count criteria to detect virological failure is poor [4]. It
is therefore not surprising that care givers are reluctant to switch patients to second-line
therapy in ART programmes without access to viral load monitoring [5, 14, 15]. We aimed
to clarify the causal effect of switching to second-line ART in such settings, using data from
two large ART programmes in Zambia and Malawi. About 13% of patients with
documented immunological failure switched to second-line ART during a median of 1.7
years of follow-up. We found that mortality from all causes was reduced by about three
quarters in patients who switched, compared to patients who did not, and that switching
earlier reduced mortality compared to switching later.Our results also indicate that targeted
viral load monitoring may further reduce mortality as it allows clinicians to selectively
switch the patients who failed virologically and probably benefit most from second-line
therapy.
The causal effect of switching to second-line therapy among immunologically failing
patients should ideally be determined in a randomized controlled trial. However, it is
unlikely that such a trial will ever be conducted: there must be ethical concerns about
withholding an intervention that has a strong biological rationale, is standard in
industrialized countries, and has been recommended by international bodies such as WHO.
Observational data like those collected for this study may thus provide the best available
evidence to inform clinical practice and public health decisions on whether and when to
switch. Confounding by prognostic factors at baseline such as age, sex and clinical stage,
andby time varying factors such as CD4 cell count may, however, distort the results from
observational studies [6, 16]. We used inverse probability of treatment weighting to adjust
for confounding by time-updated CD4 cell counts. This approach avoids the problem that
CD4 cell counts are intermediate on the causal pathway from switching to death:
confounding is controlled by weights rather than by inclusion of CD4 cell count as a
covariate in the statistical model.
The reduction in mortality associated with switching was substantial, but it may have been
diluted by unknowingly switching patients who met the immunological criteria for failure
but had undetectable viral load. In a previous study from the Lighthouse Clinic in Malawi,
viral load was measured in 203 patients with immunological or clinical failure: virological
failure was present in 54% of patients, with high levels of viral resistance to NRTIs and
NNRTIs[17, 18]. Positive predictive values were even lower in a collaborative analysis of
10 treatment programmes from Africa and Latin America [4]. In this study such dilution of
the effect of switching will have been reduced by the targeted viral load measurement done
in about half of patients who switched and about a quarter of patients who did not: viral load
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testing identifies virological failure and leads to switching in patients who benefit most.
Indeed, in a sensitivity analysis we found that the reduction in mortality associated with
switching was more pronounced in patients who had at least one viral load measurement
compared to the patients without viral load measurements, although the difference failed to
reach statistical significance. While confounding by viral load testing remains a concern,
analyses restricted to sites without viral load testing and analyses in which availability of a
prior viral load test was treated as a time dependent confounder both suggested that
switching reduced mortality, although the former result failed to reach statistical
significance. Our analyses were insufficiently powered to fully investigate these issues; we
plan additional analyses as soon as more data on patients failing ART have become
available.
Adherence is not consistently measured or reliablyrecorded in the participating cohorts and
could therefore not be included in the analysis. Low levels of adherence are associated with
poorer outcomes, both on first-line and second-line ART [15, 19] and patients perceived by
their providers to be non-adherent might also be less likely to be switched, resulting in
unmeasured confounding. In our study, adherence will generally have been lower among
patients in whom ART failed, compared to patients on non-failing first-line ART.
Interestingly, the proportion of men in our study was higher than in a recent analysis of
patients starting first-line ART in the two programmes [20], in line with the notion that
adherence is lower in men than in women [21, 22]. Men were, however, as likely to be
switched as women, indicating that documented or perceived adherence was not playing a
major role in decisions to switch or not to switch. Opportunistic infections and cancers were
also not consistently recorded. Like adherence, opportunistic events could influence
decisions; however, such confounding would be expected to lead to underestimation the
benefit of switching.Of note, in an ART programme in Mozambique, Malawi and Guinea-
Conakry only few patients met criteria for clinical failure without meeting immunological or
virological failure criteria [23].
Less than 10% of patients were lost to follow-up after experiencing immunological failure.
About twice as many patients are usually lost in the first year after starting ART [24]and
about 40% of the patients lost to follow-up die in the following months[25]. Although
follow-up was limited after starting second-line therapy, it is likely that in the present study
mortality among patients lost was also high: all patients had failed immunologically and
their CD4 cell count was therefore low by definition. We controlled for informative
censoring to the extent possible by incorporating in the weights a factor reflecting the
inverse of a subject’s estimated probability of remaining under follow-upat that time[7].
Informative censoring remains a potential source of bias, however, particularly given the
absence of death registries in Zambia and Malawi and the likelihood that some patients
failed to return to the clinic because they had died[26].
We included two public-sector programmes involved in the scale-up of ART in Zambia and
Malawi, with the Zambian programme contributing the vast majority (96.1%) of patients.
The generalizability of our results may therefore be questioned. However, the two
programmes follow national guidelines for the public health approach to ART, which is
recommended by WHO [27], and are typical for many other programmes in the region.
Results should thus be applicable to many patients in a region heavily affected by HIV. We
nevertheless acknowledge that the two sites included in this study will not be representative
for all programmes in the region. For example, they are equipped with electronic medical
record systems, have access to regular CD4 cell counts and are involved in an international
collaboration of HIV cohorts[10].
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To our knowledge this is the first study that examined the causal effect of switching to a
second-line regimenamong patients with immunological failure in a low income setting
using marginal structural models. A previous analysis of data from the United States of
America [28] used marginal structural models to estimate the effect of switching to second-
line therapy among patients with virological failure and found a hazard ratio of 0.81in
patients switching immediately compared to patients switching three months later. In a
descriptive analysis of 11 ART programmes in sub-Saharan Africa, we found that mortality
was higher in patients who switched compared to patients who remained on non-failing first-
line therapy, and substantially higher in patients who remained on immunologically or
virologically failing first-line ART[14]. These differences in mortality were not explained
by differences in nadir CD4 cell count, age or sex, but time-dependent confounding was not
considered[14].
In summary, our results suggest that in ART programmes in sub-Saharan Africa without
access to routine viral load monitoring, patients meeting the WHO immunological failure
criteria should be switched to a second-line regimen, and that delays in switching should be
avoided. Our study also suggests that unnecessary switches might be avoided by targeted
viral load; however, further research is needed to understand the barriers to switching
patients who meet failure criteria, including, for example, the limited availability of second-
line and third-line regimens, and the causal effect in patients with and without targeted viral
load measurements. Finally, future studies should investigate at what CD4 cell countlevels
patients should ideally be switched, similar to the question ofwhen ART should be
started[29], and should examine long-term outcomes, including outcomes after second-line
failure.
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Appendix
Confounding by indication will bias results if switching is more likely in patients with lower
CD4 cell counts at the time of immunological failure; patients who are also more likely to
die. Similarly, CD4 cell counts measured after failure may both affect the probability of
subsequent switching and mortality; unlike standard confounders, however, time-updated
CD4 cell counts may themselves be affected by prior switching decisions. Such
timedependent confounding can be seen as a special case of confounding by indication [6],
which cannot be controlled for by standard multivariable adjustment. These relationships
can be visualized in a directed acyclic graph [30] (DAG), as shown in a simplified version in
Figure A1.
To control for time dependent confounding we estimated the causal effect of switching on
mortality using two Cox proportional hazards marginal structural models of the
counterfactual hazard of death under alternative switching times, making the following
assumptions: (1) no unmeasured confounding of the effect of switching on mortality, (2) a
probability greater than zero of switching and not switching at each time point, regardless of
covariate values and (3) correct specification of the treatment, censoring, lost to follow-up
and outcome models.
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The parameters of these marginal structural models were estimated using inverse probability
of treatment weights (IPTW) [9]. The inverse probability of treatment weights were
stabilised and included additional censoring and loss to follow up components [8]. The
treatment weight for a given time point was based on the inverse of a patient’s estimated
probability of having his or her observed switching history up to that time point, given his or
her treatment and covariate history. Thus, for each quarter we estimated the probability of
switching to second-line ART in that quarter among patients who had not already switched
using Cox regression with predictors including all baseline covariates together with most
recent CD4 cell count and the (lagged) CD4 cell count from the previous quarter. Most
recent CD4 cell count refers to the last CD4 cell count before switching within a quarter. For
each weight model three different structures were considered: (1) a simple linear model on
the log-hazard scale including all predictors described above; (2) a linear model on the log-
hazard scale where nonlinear associations were incorporated using natural cubic splines and
(3) the best fitting linear model on the log-hazard scale based on AIC forward/backward
stepwise selection procedure.
We used generalised additive models to assess linearity of the association between CD4 cell
count and the log-hazard of switching.
P-values correspond to tail probabilities of the coefficients’ posterior distributions.
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Figure 1. Estimated effect of switching to second-line therapy on all cause mortality among
patients experiencing immunological failure, using unweighted(crude and adjusted) and
weighted (causal) Cox models
Upper panel: HR for immediate switching compared to patients remaining on first-line
regimen.
Lower panel: HR for each additionalsix month delay until switching.
Hazard ratios with 95% credibility intervals are shown.
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Figure 2. Predicted survival in women younger than 30 years in stage III/IV with a baseline CD4
cell count between 100 and 199cells/μL after immunological failure
Survival curves for immediate switching to second-line antiretroviral therapy, switching
after 6,12 and 18 months and not switching are shown.
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Figure A1. Directed acyclic graph (DAG) illustrating time-dependent confounding in a setting
with 2 time points and omitting baseline and unmeasured confounders
Arrows represent direct causal relationships between variables.
CD4 cell count at a given time point (e.g. t=0) not only determines if therapy is switched to
a second-line regimen at some time point (e.g. t=0 or t=1, arrows a and b) but also
influences CD4 cell count at a later time point (e.g. t=1, arrow c) and mortality (arrow d).
Switching at a given time point (e.g. t=0) also influences CD4 cell count and switching at
later time points (e.g. t=1, arrows e and f) and mortality (arrow g). Similarly, CD4 cell count
at time point t=1 and switching at time point t=1 influence mortality (arrows h and i).
Finally, switching at time point t=1 influences mortality (arrow j).
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Table 1
Characteristics of patients failing first-line antiretroviral therapy based on immunological criteria at start of
therapy and at failure, in patients who subsequently switched versus those who did not switch to second-line
therapy
At start of ART At immunological failure
Switched
(n=324)
Did not switch
(n=2,087)
P Switched
(n=324)
Did not switch
(n=2087)
P
Age (years) 0.57 0.78
 < 30 215 (66.4%) 1368 (65.5%) 179 (55.3%) 1157 (55.5%)
 30-39 93 (28.7%) 584 (28.0%) 119 (36.7%) 740 (35.4%)
 ≥40 16 (4.9%) 135 (6.5%) 26 (8.0%) 190 (9.1%)
 Median (IQR) 26 (23-31) 27 (23-32) 29 (25-33) 29 (25-34)
Sex 0.76 0.76
 Female 169 (52.2%) 1107 (53.1%) 169 (52.2%) 1107 (53.1%)
 Male 155 (47.8%) 980 (46.9%) 155 (47.8%) 980 (46.9%)
CD4 cell count
(cells/μL) *
<0.001 <0.001
 < 50 99 (35.1%) 371 (19.2%) 100 (30.9%) 225 (10.8%)
 50-99 61 (21.6%) 296 (15.3%) 104 (32.1%) 481 (23.1%)
 100-199 51 (18.1%) 539 (27.9%) 87 (26.8%) 676 (32.4%)
 ≥200 71 (25.2%) 726 (37.6%) 33 (10.2%) 705 (33.8%)
 Median (IQR) 80 (32-204) 155 (64-279) 77 (41-133) 146 (82-232)
WHO clinical stage 0.73
 I/II 89 (27.5%) 555 (26.6%) Not available Not available
 III/IV 235 (72.5%) 1532 (73.4%)
*CD4 cell count at start of ART missing in 197 patients
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Table 2
Antiretroviral regimens in patients experiencing immunological failure, separately for those who switched and
those who did not switch to second-line therapy
Patients who switched
(n=324)
Patients who did not switch
(n=2,086)
First-line regimen
 3TC AZT NVP 172 (53.1%) 1043 (50.0%)
 3TC d4T NVP 126 (38.9%) 879 (42.1%)
 3TC d4T EFV 14 (4.3%) 75 (3.6%)
 3TC AZT EFV 11 (3.4%) 86 (4.1)
 Other 1 (0.3%) 3 (0.2%)
Second-line regimen Not applicable
 ETC LPV TNV 194 (59.9%)
 ABC DDI LPV 65 (20.1%)
 ATZ ETC LPV TNV 15 (4.6%)
 ATZ 3TC LPV/r TNV 14 (4.3%)
Other 36 (11.1%)
Numbers on regimen (%) are shown.
P=0.65 by chi-squared test for difference between first-line regimens.
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Table 3
Predictors of switching to second-line antiretroviral therapy after immunological failure
Adjusted*Haza
rd ratio
95% CI P
Current CD4 cell count
( per 100 cells /μL )
0.49 (0.36-0.67) <0.001
Lagged CD4 cell count
( per 100 cells /μL )
0.98 (0.71-1.35) 0.90
Age (years)
< 30 1 0.43
 30-39 1.08 (0.84-1.40)
≥40 0.76 (0.46-1.27)
 Median (IQR)
Sex
 Female 1.11 (0.89-1.40) 0.32
 Male 1
Baseline CD4 cell count
(cells/μL)
< 50 1 0.096
 50-99 0.66 (0.49-0.89)
 100-199 0.68 (0.47-0.99)
≥200 0.70 (0.38-1.29)
WHO clinical stage
 I/II 1
 III/IV 0.85 (0.66-1.09) 0.13
*From multivariate Cox regression model adjusted for all variables listed.
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